{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:12:59Z","timestamp":1778091179980,"version":"3.51.4"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Prostate-specific membrane antigen (PSMA)-based imaging has become an increasingly important diagnostic tool in prostate cancer, though limited by low surface expression of PSMA in some patients. Previous studies have demonstrated that dutasteride can induce PSMA expression\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      . This pilot study aimed to evaluate the impact of short-term dutasteride treatment on standardized uptake values (SUVmax) in PSMA PET imaging and the immunohistochemical expression of PSMA for the first time in humans.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four prostate cancer (PCa) patients underwent an initial PSMA PET\/MRI of the prostate. Afterwards, all patients received 0.5 mg of oral dutasteride once daily for seven days. Subsequently, a second PSMA PET\/MRI of the prostate and a template biopsy were performed. We compared the maximum standardized uptake value (SUVmax) of PSMA-positive lesions before and after dutasteride treatment. Additionally, histopathological specimens from PSMA-positive lesions and negative controls were analyzed for Gleason score and PSMA expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An increase in SUVmax was observed in all patients following short-term dutasteride treatment. Histological analysis confirmed prostate cancer with an ISUP grade of \u2265 2 in PSMA-positive lesions that exhibited increased SUVmax following short-term stimulation. One PSMA-positive lesion, which showed a decrease in SUVmax after stimulation, was negative for prostate cancer on biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pilot study demonstrated an increase in SUVmax in PSMA-positive prostate cancer lesions following a short-term seven-day course of dutasteride. Short-term dutasteride treatment prior to PSMA-PET imaging may have the potential to enhance detection rates in patients with prostate cancer. Further studies are needed to investigate this effect in larger patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0348695","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:31:47Z","timestamp":1778088707000},"page":"e0348695","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dutasteride treatment and its effect on standardized uptake values in prostate-specific membrane antigen-PET imaging: A pilot study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2414-2521","authenticated-orcid":true,"given":"Lucas","family":"Praetzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.","family":"R\u00fcschoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels J.","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Eberli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Kranzb\u00fchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"2","key":"pone.0348695.ref001","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"RS Israeli","year":"1993","journal-title":"Cancer Res"},{"issue":"1","key":"pone.0348695.ref002","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00259-024-06856-x","article-title":"Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer","volume":"52","author":"NJ Rupp","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"pone.0348695.ref003","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases","volume":"82","author":"DG Bostwick","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"pone.0348695.ref004","first-page":"715","article-title":"Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia","volume":"19","author":"C Marchal","year":"2004","journal-title":"Histol Histopathol"},{"issue":"10231","key":"pone.0348695.ref005","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"MS Hofman","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"pone.0348695.ref006","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.urolonc.2013.09.003","article-title":"The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research","volume":"32","author":"BT Ristau","year":"2014","journal-title":"Urol Oncol"},{"issue":"1","key":"pone.0348695.ref007","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-017-3850-x","article-title":"Clinical performance of 68Ga-PSMA-11 PET\/MRI for the detection of recurrent prostate cancer following radical prostatectomy","volume":"45","author":"B Kranzb\u00fchler","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"pone.0348695.ref008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.12954\/PI.14054","article-title":"Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice","volume":"2","author":"B Lojanapiwat","year":"2014","journal-title":"Prostate Int"},{"issue":"6","key":"pone.0348695.ref009","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.eururo.2013.08.013","article-title":"Early salvage radiotherapy following radical prostatectomy","volume":"65","author":"D Pfister","year":"2014","journal-title":"Eur Urol"},{"issue":"30","key":"pone.0348695.ref010","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"RD Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"issue":"32","key":"pone.0348695.ref011","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer","volume":"34","author":"BJ Stish","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0348695.ref012","unstructured":"cancer EGPoP. EAU Guidelines on Prostate Cancer. Arnhem, the Netherlands: EAU Guidelines Office. 2025."},{"issue":"3","key":"pone.0348695.ref013","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22910","article-title":"Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer","volume":"75","author":"JD Murga","year":"2015","journal-title":"Prostate"},{"issue":"1","key":"pone.0348695.ref014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"B Meller","year":"2015","journal-title":"EJNMMI Res"},{"issue":"1","key":"pone.0348695.ref015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients","volume":"47","author":"S Vaz","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"pone.0348695.ref016","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0970-1591.52907","article-title":"Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues","volume":"25","author":"A Bagrodia","year":"2009","journal-title":"Indian J Urol"},{"issue":"10","key":"pone.0348695.ref017","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells","volume":"78","author":"B Kranzb\u00fchler","year":"2018","journal-title":"Prostate"},{"issue":"6","key":"pone.0348695.ref018","article-title":"Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model","volume":"4","author":"B Kranzb\u00fchler","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"4","key":"pone.0348695.ref019","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bju.16213","article-title":"Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial","volume":"133","author":"B Kaufmann","year":"2024","journal-title":"BJU Int"},{"issue":"2","key":"pone.0348695.ref020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2967\/jnumed.118.225276","article-title":"Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET\/MRI in Patients with Low PSA Values \u2264 0.5 ng\/mL","volume":"61","author":"B Kranzb\u00fchler","year":"2020","journal-title":"J Nucl Med"},{"issue":"10","key":"pone.0348695.ref021","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00259-021-05261-y","article-title":"Diagnostic performance of 68Ga-PSMA-11 PET\/MRI-guided biopsy in patients with suspected prostate cancer: A prospective single-center study","volume":"48","author":"DA Ferraro","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"pone.0348695.ref022","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2967\/jnumed.123.266164","article-title":"Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for prostate cancer diagnosis within a real-world database","volume":"65","author":"L Emmett","year":"2024","journal-title":"J Nucl Med"},{"issue":"2","key":"pone.0348695.ref023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5114\/jcb.2011.23203","article-title":"BiopSee\u00ae - transperineal stereotactic navigated prostate biopsy","volume":"3","author":"P Zogal","year":"2011","journal-title":"J Contemp Brachytherapy"},{"issue":"1","key":"pone.0348695.ref024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: Renal, penile, and testicular tumours","volume":"70","author":"H Moch","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"pone.0348695.ref025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System","volume":"40","author":"JI Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"pone.0348695.ref026","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","article-title":"First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands","volume":"60","author":"NJ Rupp","year":"2019","journal-title":"J Nucl Med"},{"issue":"4","key":"pone.0348695.ref027","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","author":"Y Kinoshita","year":"2006","journal-title":"World J Surg"},{"issue":"1","key":"pone.0348695.ref028","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","author":"GL Wright","year":"1995","journal-title":"Urol Oncol"},{"issue":"12","key":"pone.0348695.ref029","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1007\/s00259-021-05501-1","article-title":"What\u2019s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns","volume":"48","author":"JH R\u00fcschoff","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"pone.0348695.ref030","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"DA Silver","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"9","key":"pone.0348695.ref031","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.crad.2024.05.013","article-title":"Prostate specific membrane antigen (PSMA) avid nonprostatic benign and malignant disease: A pictorial review","volume":"79","author":"R Srinivasan","year":"2024","journal-title":"Clin Radiol"},{"issue":"1","key":"pone.0348695.ref032","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"MS Hofman","year":"2018","journal-title":"Radiographics"},{"issue":"17","key":"pone.0348695.ref033","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum imaging strategies for advanced prostate cancer: ASCO Guideline","volume":"38","author":"EJ Trabulsi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"pone.0348695.ref034","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.3390\/ijms25179755","article-title":"Prostate-specific membrane antigen biology and pathophysiology in prostate carcinoma, an update: Potential implications for targeted imaging and therapy","volume":"25","author":"J Maes","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0348695.ref035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"MK Bakht","year":"2025","journal-title":"Nat Rev Urol"},{"issue":"3","key":"pone.0348695.ref036","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","article-title":"Prostate-specific membrane antigen-targeted therapies for prostate cancer: Towards improving therapeutic outcomes","volume":"85","author":"M Corpetti","year":"2024","journal-title":"Eur Urol"},{"key":"pone.0348695.ref037","doi-asserted-by":"crossref","first-page":"101045","DOI":"10.1016\/j.neo.2024.101045","article-title":"Regulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells after treatment with dutasteride and lovastatin","volume":"57","author":"A Kuzmanov","year":"2024","journal-title":"Neoplasia"},{"issue":"12","key":"pone.0348695.ref038","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/pros.23868","article-title":"Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells","volume":"79","author":"B Kranzb\u00fchler","year":"2019","journal-title":"Prostate"},{"key":"pone.0348695.ref039","unstructured":"Deutsche Krebsgesellschaft DK. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3-Leitlinie Prostatakarzinom. 2021."},{"key":"pone.0348695.ref040","unstructured":"EAU Guidelines Office A. EAU Guidelines. 2023."},{"issue":"1","key":"pone.0348695.ref041","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, risk assessment, staging, and risk-based management","volume":"208","author":"JA Eastham","year":"2022","journal-title":"J Urol"},{"issue":"8","key":"pone.0348695.ref042","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2967\/jnumed.119.236083","article-title":"Quantitative test-retest measurement of 68Ga-PSMA-HBED-CC in tumor and normal tissue","volume":"61","author":"JH Pollard","year":"2020","journal-title":"J Nucl Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0348695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:31:55Z","timestamp":1778088715000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0348695"}},"subtitle":[],"editor":[{"given":"Matteo","family":"Bauckneht","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0348695","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}